Skip to main content
    • Blog  / 
    • August 23, 2023

    Our Year So Far

    It is hard to believe that we are already more than halfway through the year. Although time has passed quickly, the last few months have been hugely rewarding for Koning and our quest for better health for women.

    Here are some of our 2023 highlights, so far:

    Firstly, on March 9th, the FDA announced that exams scanning dense breasts on mammography are indeterminate and require secondary imaging. Since dense breast tissue has presented a significant challenge to radiologists with present technology, this breakthrough gave a great opportunity for our work and the people we aim to serve. 39 states have enacted similar legislation in the past, but this pronouncement officially made this a federally supported issue. The FDA pronouncement triggered legislative action across numerous states that now have state-wide mandates for the coverage and payment of supplemental imaging, paving the way for Breast CT to fill this critical gap. Given the exceptional capability of our technology in imaging dense breast tissue, our solutions are remarkably well-placed to serve this community.

    Secondly, orders for our Koning Vera Breast CT have surged since our participation in the Society of Breast Imaging Symposium in May. Our discussions during the symposium also served as a fantastic platform to showcase the impact our technology can have, leading to an overwhelmingly positive reception from the clinical community.

    To ensure that healthcare providers are equipped with the best tools to provide early and accurate diagnosis, we have also been collaborating with a number of hospitals to offer Koning Vera Breast CT as the secondary imaging for women with dense breasts. Earlier this summer, our distributor partner Advanced Southern Imaging attended the annual ACOG conference in Baltimore and noticed significant acceptance of Breast CT as an effective no-compression option for breast exams. In addition to increasing enthusiasm for Breast CT, our partners have also been able to generate interest for placement in multiple facilities across the country.

    All of these recent achievements add to our aim of creating a breakthrough in conventional breast cancer detection. Stay tuned for more updates, we are thrilled to see what the remainder of the year has in store!

    Share